This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Niagen Bioscience (NAGE) and Gilead Sciences (GILD)

Tipranks - Tipranks - Thu Aug 6, 11:02AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Niagen Bioscience (NAGE) and Gilead Sciences (GILD) with bullish sentiments.

Claim 55% Off TipRanks

Niagen Bioscience (NAGE)

Canaccord Genuity analyst Susan Anderson maintained a Buy rating on Niagen Bioscience today and set a price target of $10.00. The company’s shares closed last Wednesday at $3.13, close to its 52-week low of $2.31.

According to TipRanks.com, Anderson is a 5-star analyst with an average return of 17.4% and a 46.8% success rate. Anderson covers the NA sector, focusing on stocks such as Peloton Interactive, Sally Beauty, and Ulta Beauty. ;'>

Currently, the analyst consensus on Niagen Bioscience is a Strong Buy with an average price target of $10.20, implying a 228.0% upside from current levels. In a report released yesterday, TipRanks – PerPlexity also upgraded the stock to Buy with a $4.00 price target.

See the top stocks recommended by analysts >>

Gilead Sciences (GILD)

BMO Capital analyst Evan Seigerman maintained a Buy rating on Gilead Sciences yesterday and set a price target of $174.00. The company’s shares closed last Wednesday at $129.63.

According to TipRanks.com, Seigerman is a 5-star analyst with an average return of 7.7% and a 56.1% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, ACADIA Pharmaceuticals, and Vertex Pharmaceuticals. ;'>

Currently, the analyst consensus on Gilead Sciences is a Strong Buy with an average price target of $159.00, implying a 16.9% upside from current levels. In a report issued on July 22, Bernstein also maintained a Buy rating on the stock with a $160.00 price target.

Read More on NAGE:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).